HEPIUS Tirzepatide 500mcg CAS:2023788-19-2

*Tirzepatide (Chinese name: Tirzepatide) is an innovative peptide drug currently developed and marketed by Eli Lilly under the brand name **Mounjaro**. **HEPIUS** may be an unofficial brand or supply channel name associated with Tirzepatide (pending confirmation). Here are the details about Tirzepatide:

### **1. Drug Overview**

Tirzepatide is a dual agonist that acts simultaneously on two incretin receptors:

- **GLP-1 (Glucagon-like peptide-1) receptor**

- **GIP (glucose-dependent insulin-releasing polypeptide) receptor**

This dual mechanism of action gives Tirzepatide significant advantages in both blood sugar control and weight management.

### **2. Physical and chemical properties**

- **Molecular structure**: Tirzepatide is a synthetic peptide containing 39 amino acid residues linked to its backbone by fatty acid chains to extend the drug half-life.

- **Molecular weight**: Approximately 4813.6 Da (Daltons).

- **Solubility**: This drug is generally formulated in the form of an aqueous solution for subcutaneous injection.

- **Appearance**: Mostly colorless or light yellow transparent liquid.

### **3. Pharmacokinetics**

- **Dosage**: Tirzepatide is administered by injection under the skin, usually once a week.

- Starting dose: **2.5 mg/week**

- Usual maintenance dose: **5-15 mg/week** (adjusted based on patient tolerance and treatment goals).

- **Half-life**: **Approximately 5 days (120 hours)**. Its long-acting properties make once-weekly dosing possible.

- **Metabolism and excretion**:

- Mainly metabolized by proteases.

-Degradation products of the drug are excreted in urine and feces.

### **4. Mechanism of Action**

Tirzepatide activates the following pathways via GLP-1 and GIP receptors:

1. **Lower blood sugar**:

- Promotes insulin secretion from pancreatic β cells (glucose-dependent).

- Inhibits the secretion of glucagon by pancreatic alpha cells.

- Delay gastric emptying and reduce postprandial blood sugar fluctuations.

2. **Weight loss**:

- Reduces food intake by suppressing appetite-related central mechanisms.

- Increase basal metabolic rate.

### **5. Clinical Application**

1. **Type 2 Diabetes Mellitus (T2DM)**: Tirzepatide has been approved to improve glycemic control, especially for patients who have failed to respond to monotherapy or combination therapy.

2. **Weight management** (still under study): Tirzepatide has a very significant weight loss effect in obese or overweight people, and its indications are gradually being expanded.

### **6. Treatment cycle**

- Usually adjusted according to the individual patient's situation, **the initial phase is 4 weeks**, and then gradually increased to the target dose.

- The course of treatment generally lasts from 6 months to 1 year, and blood sugar, weight, cardiovascular indicators, etc. need to be monitored regularly.

### **7. Adverse reactions and precautions**

1. **Common adverse reactions**:

- Gastrointestinal symptoms: nausea, vomiting, diarrhea, constipation.

- Hypoglycemia (usually occurs when used in combination with other glucose-lowering drugs).

- Decreased appetite.

2. **Serious but rare adverse reactions**:

- Pancreatitis.

- Gallbladder disease.

- Risk of thyroid C-cell tumors (found in animal studies).

3. **Contraindications**:

- Personal or family history of medullary thyroid cancer.

- Patients with a history of multiple endocrine neoplasia syndrome type 2.

### **8. Clinical research data**

- In multiple clinical trials (SURPASS series of studies), Tirzepatide has demonstrated significant blood sugar control and weight loss effects, which are superior to GLP-1 agonists (such as semaglutide).

- **Weight loss data**: Patients in the high-dose group (15 mg/week) achieved an average weight loss of more than 20%.

### **9. Precautions for use**

- **Injection site selection**: Usually the abdomen, thigh or upper arm, the site needs to be rotated.

- **Storage conditions**: Keep refrigerated (2-8°C), avoid freezing.

*Tirzepatide, under the HEPIUS brand, is a new type of glucose-lowering drug, primarily used to treat type 2 diabetes. It has also shown potential therapeutic effects on obesity and metabolic syndrome in clinical studies. The following is a detailed description of the drug's applicable population, working principle, and usage and dosage:

### **Target Audience**

1. **Patients with type 2 diabetes**: Tirzepatide is mainly used to improve blood sugar control in patients with type 2 diabetes, especially for those patients who cannot adequately control their blood sugar through diet control and exercise.

2. **Obese or overweight people with metabolic diseases** (under study): This drug shows significant weight management effects and can be used for weight loss in obese or overweight people.

3. **Diabetic patients at risk of cardiovascular disease**: Clinical studies have shown that Tirzepatide may help improve cardiovascular metabolic indicators and is particularly beneficial for high-risk patients.

### **How ​​it works**

Tirzepatide is a **dual agonist** with a unique and complex mechanism of action:

1. **Targeting GLP-1 and GIP receptors**:

- **GLP-1 receptor** (glucagon-like peptide-1 receptor): lowers blood sugar and controls weight by stimulating insulin secretion, inhibiting glucagon release, delaying gastric emptying, and increasing satiety .

- **GIP Receptor** (Glucose-dependent Insulin-releasing Polypeptide Receptor): Further improves metabolic function by enhancing insulin sensitivity and inhibiting fat storage.

2. **Comprehensive metabolic effects**:

- Reduce hepatic glucose output and lower fasting blood sugar.

- Promote the improvement of pancreatic β-cell function and delay the progression of diabetes.

- Suppresses appetite and promotes energy expenditure, leading to weight loss.

### **Usage and Dosage**

1. **Dosage form and specifications**:

- Tirzepatide is usually administered as a subcutaneous injection and is available in a variety of dosage strengths (e.g. 2.5 mg, 5 mg, 10 mg, 15 mg, etc.).

2. **Starting dose**:

- The starting dose is usually 2.5 mg subcutaneously once a week.

- After 4 weeks, gradually increase to the target dose (e.g., 5 mg/week or higher) to maximize the balance between efficacy and tolerability.

3. **Dosage adjustment**:

- The dose may be increased gradually based on the patient's individual response, tolerability, and glycemic control goals.

- The maximum recommended dose is usually 15 mg/week, but the specific regimen needs to be adjusted by the doctor according to the patient's condition.

4. **Injection site**:

- Subcutaneous injections can be given in the abdomen, thigh or upper arm, with different injection sites chosen each week to avoid local irritation.

### **Notes**

1. **Contraindications**:

- Patients with medullary thyroid cancer or family history of the disease.

- Patients with multiple endocrine neoplasia syndrome type II.

- Patients with hypersensitivity to Tirzepatide or its ingredients.

2. **Common side effects**:

- Gastrointestinal discomfort such as nausea, vomiting, diarrhea, and constipation.

- Hypoglycemia (especially when used in combination with other glucose-lowering drugs).

- Mild injection site reactions.

3. **Combination use with other drugs**:

- It can be used in combination with other glucose-lowering drugs (such as metformin, SGLT-2 inhibitors), but attention should be paid to the risk of hypoglycemia.

4. **Pregnancy and lactation**:

- Not recommended for use by pregnant or breastfeeding women. Consult a doctor for specific circumstances.

### **Conclusion**

Tirzepatide is an innovative drug with significant blood sugar lowering and weight reduction effects, providing a new treatment option for patients with type 2 diabetes and obese people. However, the use of drugs must strictly follow the doctor's instructions and regularly monitor blood sugar and related health indicators to ensure the safety and effectiveness of treatment.

Tirzepatide is a novel antidiabetic drug with unique versatility and significant clinical advantages. HEPIUS-branded Tirzepatide further enhances the efficacy and market competitiveness of this drug through its innovative research and development and high-quality production in the treatment of diabetes and related metabolic diseases. The following is a detailed introduction to the advantages of HEPIUS brand Tirzepatide:

### **1. Uniqueness of the drug's mechanism of action**

Tirzepatide is a dual receptor agonist of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Compared with traditional single-action hypoglycemic drugs, it has the following advantages:

- **Dual-target synergistic effect**: Activates GLP-1 and GIP receptors simultaneously, significantly enhancing the hypoglycemic effect.

- **Improve insulin secretion**: Promote the secretion of insulin by pancreatic β cells, while inhibiting the secretion of glucagon by pancreatic α cells.

- **Reduce pancreatic cell stress**: Protect pancreatic islet function and delay the progression of diabetes.

### **2. Significant clinical effects**

Tirzepatide has demonstrated significant efficacy in multiple clinical trials, such as the SURPASS series of trials, including:

- **Better blood sugar control**: Compared with other glucose-lowering drugs, Tirzepatide can more significantly reduce HbA1c (glycosylated hemoglobin), and some patients can even achieve blood sugar levels close to those of non-diabetics.

- **Outstanding weight management effect**: Tirzepatide not only has a strong blood sugar lowering effect, but also can significantly reduce body weight by regulating appetite and promoting fat decomposition. Some patients can lose more than 20% of their weight after 12-18 months of treatment.

- **Cardiovascular Protection**: Studies have shown that Tirzepatide reduces the risk of cardiovascular events (such as heart attack, stroke, etc.), especially in diabetic patients at risk of cardiovascular disease.

### **3. Efficient persistence**

Tirzepatide is administered as a once-weekly injection. This long-acting injection mechanism:

- Reduce the frequency of medication for patients and improve compliance.

- Release drug efficacy continuously and stably to avoid blood sugar fluctuations.

- For patients on long-term treatment, the quality of life improves significantly.

### **4. HEPIUS brand's innovative advantages**

As the developer and producer of Tirzepatide, HEPIUS brand has the following unique competitive advantages in the market through unique process technology and strict quality control:

- **High purity and high activity**: HEPIUS uses advanced synthesis and purification technologies to ensure the high purity of Tirzepatide and reduce side effects.

- **Accessibility and Affordability**: Compared with other brands, HEPIUS has optimized the production process, reduced production costs, and provided patients with a more affordable option.

- **Product stability**: HEPIUS's Tirzepatide products show higher stability during storage and transportation, and are suitable for a variety of market environments.

- **Global supply chain layout**: HEPIUS's extensive market network enables Tirzepatide to quickly cover the global market and meet the needs of more patients.

### **5. Wide range of indications**

In addition to its significant effect in the treatment of type 2 diabetes, Tirzepatide also shows potential application prospects in the following areas:

- **Obesity Treatment**: Tirzepatide is being extensively studied as a weight management drug for obese patients with the potential to outperform other drugs currently on the market.

- **Non-alcoholic fatty liver disease (NAFLD)**: Preliminary studies have shown that Tirzepatide may improve hepatic steatosis and become a new treatment option for NAFLD and non-alcoholic steatohepatitis (NASH).

- **Multiple metabolic diseases**: Comprehensive management of complications including hypertension, dyslipidemia, etc.

### **6. Improved patient experience**

HEPIUS brand Tirzepatide is patient-centric and focuses on optimizing the patient experience:

- **Simple injection device**: Equipped with an easy-to-use automatic injection device to improve the convenience of medication.

- **Reduce adverse reactions**: HEPIUS reduces the incidence of common adverse reactions such as nausea and vomiting by improving the formula.

WhatsApp/Telegram:+852 6749 2648

Gmail:lucasraws207@gmail.com

Skype：live:.cid.8f21dc7fc6621ba7

Hot Tags: hepius tirzepatide 500mcg cas:2023788-19-2, China hepius tirzepatide 500mcg cas:2023788-19-2 manufacturers, suppliers, factory, Viagra Improves the pump and muscle definition during training, steroid finished, steroid finished tablets, Methyltest Improve strength performance, Methyltest CAS 879190 14 4, Methyltrienolone Highly effective fat reduction